Setrusumab did not meet primary fracture endpoints in the ORBIT and COSMIC trials but significantly improved bone mineral density in patients with osteogenesis imperfecta. Topline data were announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results